Sotatercept (mIgG2a)

Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) [1][2][3][4].

Product Specifications

Product Name Alternative

RAP-011

UNSPSC

12352203

Target

TGF-beta/Smad; TGF-β Receptor

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/sotatercept-migg2a.html

Purity

99.93

Solubility

10 mM in DMSO

Smiles

[Sotatercept(mIgG2a)]

Molecular Weight

(79.67 kDa)

References & Citations

[1]Morse A, et al. RAP-011 augments callus formation in closed fractures in rats. J Orthop Res. 2016 Feb;34 (2) :320-30.|[2]Langdon JM, et al. RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol. 2015 Jan;90 (1) :8-14. |[3]Agapova OA, et al. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int. 2016 Jun;89 (6) :1231-43. |[4]De Rosa G, et al. RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway. Int J Mol Sci. 2020 Aug 4;21 (15) :5577.